SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome

Rhea-AI Summary

SciSparc (Nasdaq: SPRC) announced that subsidiary NeuroThera Labs (TSXV: NTLX) has initiated a Phase IIb clinical trial site at Hannover Medical School in Germany for SCI-110, a proprietary cannabinoid-based candidate for treating Tourette Syndrome (TS) in adults.

The trial, previously cleared by Germany’s Federal Institute for Drugs and Medical Devices and MHH’s ethics committee, is a randomized, double-blind, placebo-controlled, cross-over study assessing daily oral SCI-110. It will also enroll at Yale Child Study Center in the US and Tel Aviv Sourasky Medical Center in Israel. According to SciSparc, the Phase IIa study showed an average 21% tic reduction on the Yale Global Tic Severity Scale, and Phase IIb will evaluate efficacy, safety, and tolerability in adults aged 18–65, using tic severity change at weeks 12 and 26 as the primary endpoint.

Positive

• Phase IIb site initiated at Hannover Medical School in Germany
• Global multicenter design with sites in Germany, United States, and Israel
• Phase IIa data showed 21% average tic reduction on standard severity scale
• Rigorous trial design randomized, double-blind, placebo-controlled, cross-over
• Adult TS focus targeting patients aged 18–65 with unmet treatment needs

Negative

• None.

Market reaction after Phase IIb clinical trial initiation: SPRC +14.75% in the Jul 15 session

+14.75% 3.0x vol

9 alerts

+14.75% Session close to close

+21.3% Peak in 31 hr 18 min

$2.62M Market Cap

3.0x Rel. Volume

In the Jul 15 session, SPRC gained 14.75%, reflecting a significant positive market reaction. Argus tracked a peak move of +21.3% during that session. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. Trading volume was very high at 3.0x the daily average, suggesting strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +14.8% in the session following this news. If shares had jumped sharply, it would h...

Analysis

The stock surged +14.8% in the session following this news. If shares had jumped sharply, it would have contrasted with past clinical-trial headlines, which on average moved about -10.63%. Investors might have treated this as a reset of that pattern, though resale overhang from the active F-3 could cap follow-through.

Key Figures

Average tic reduction: 21% Patient age range: 18-65 years Primary endpoint timing: Weeks 12 and 26

3 metrics

Average tic reduction 21% Phase IIa study of SCI-110 in Tourette Syndrome

Patient age range 18-65 years Inclusion criteria for Phase IIb SCI-110 trial

Primary endpoint timing Weeks 12 and 26 Yale Global Tic Severity Scale change vs baseline

Previous Clinical trial Reports

2 past events · Latest: Dec 31 (Positive)

Same Type Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
Dec 31	Clinical trial renewal	Positive	-22.7%	Renewal of approval for SCI-210 autism clinical trial in Israel.
Aug 19	Patient enrollment update	Positive	+1.4%	Enrollment and dosing of first five patients in SCI-210 autism trial.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Clinical-trial headlines for SciSparc have shown mixed reactions, with tag-specific moves averaging a decline.

Key Terms

phase iib, double-blind, placebo-controlled, yale global tic severity scale, +1 more

5 terms

phase iib medical

"announced the initiation of its Phase IIb clinical trial site"

Phase IIb is a mid-stage clinical trial that tests whether an experimental treatment works and what dose is best by studying it in a larger group of patients than early tests. For investors, Phase IIb results are important because they substantially reduce uncertainty about a drug’s effectiveness and safety, and positive or negative outcomes often drive company valuation, partnership interest, and the likelihood of advancing to the large, costly Phase III trials.

double-blind medical

"Phase IIb study is a randomized, double-blind, placebo-controlled, cross-over trial"

A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.

placebo-controlled medical

"Phase IIb study is a randomized, double-blind, placebo-controlled, cross-over trial"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

yale global tic severity scale medical

"measured by the gold standard, Yale Global Tic Severity Scale Total Tic Score"

A clinician-rated questionnaire that measures the severity and impact of motor and vocal tics, including number, frequency, intensity, complexity and overall impairment. Think of it like a standardized report card for tics used in clinical care and drug trials; it matters to investors because scores are commonly used as an objective endpoint in research and regulatory filings, which can influence trial outcomes, approval prospects and commercial value of treatments.

adverse events medical

"Safety will be assessed through monitoring of adverse events."

Adverse events are any harmful or unwanted medical occurrences experienced by people using a drug, device, or undergoing a treatment, whether or not the problem is caused by the product. Think of them as complaints or breakdowns noticed during a trial or after a product is on the market; regulators record and investigate them. Investors care because clusters or serious adverse events can delay approvals, trigger costly studies or recalls, change labeling, and quickly alter a company’s revenue and risk profile.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TEL AVIV, Israel, July 15, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its subsidiary NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, announced the initiation of its Phase IIb clinical trial site at  Hannover Medical School, Hanover, Germany (“MHH”), for SCI-110, its proprietary cannabinoid-based treatment candidate for Tourette Syndrome (TS) in adults.

The trial, which previously received regulatory clearance from Germany’s Federal Institute for Drugs and Medical Devices and MHH's ethics committee, is now advancing towards the next stage at Hannover Medical School, one of the key clinical sites of the study. SCI-110 combines dronabinol with the endocannabinoid-like palmitoylethanolamide in an innovative one dosage form designed to reduce tics and comorbid symptoms in adults with TS while minimizing side effects.

In addition to Hannover Medical School, the trial will be conducted at Yale Child Study Center in New Haven, Connecticut, and Tel Aviv Sourasky Medical Center in Tel Aviv, Israel.

Building on the positive safety and efficacy results from the Phase IIa study, which showed an average tic reduction of 21% across the entire participants sample, as measured by the gold standard, Yale Global Tic Severity Scale Total Tic Score scale, the Phase IIb study is a randomized, double-blind, placebo-controlled, cross-over trial designed to evaluate the efficacy, safety, and tolerability of daily oral SCI-110. Patients aged 18-65 will be randomized to receive either SCI-110 or placebo, with the primary efficacy endpoint being the change in tic severity measured by the Yale Global Tic Severity Scale at weeks 12 and 26 compared to the baseline. Safety will be assessed through monitoring of adverse events.

Dr. Adi Zuloff-Shani, Chief Technology Officer of NeuroThera Labs, commented: “The initiation of the German site marks an important step forward in our global development program for SCI-110. Tourette Syndrome is an unmet medical need condition with limited treatment options, particularly in adults who experience persistent, severe, and debilitating symptoms. We believe SCI-110 has the potential to offer a novel, more effective and safer alternative. We are committed to advancing this promising therapy and delivering meaningful data to support its future approval.”

About SciSparc Ltd. (Nasdaq: SPRC):

The Company, through its majority-owned subsidiary NeuroThera, engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera, is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation; and SCI- 210 for the treatment of Autism Spectrum Disorder and status epilepticus. The Company, through NeuroThera, also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace.

About NeuroThera Labs Inc.

NeuroThera Labs Inc. (TSXV: NTLX) is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses the conduct, progress and expected timing of NeuroThera’s Phase IIb clinical trial of SCI-110 for the treatment of TS; the anticipated participation of additional clinical trial sites, including the Yale Child Study Center and the Tel Aviv Sourasky Medical Center; patient enrollment and randomization; the evaluation of the efficacy, safety and tolerability of SCI-110; the potential of SCI-110 to offer a novel or safer alternative to existing treatments; the generation of data to support future regulatory approval; and the continued development and potential commercialization of SCI-110. Because such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F, filed with the SEC on April 29, 2026, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055

FAQ

What did SciSparc (SPRC) announce about Tourette Syndrome treatment on July 15, 2026?

SciSparc announced initiation of a Phase IIb clinical trial site in Germany for SCI-110, its cannabinoid-based Tourette Syndrome treatment candidate in adults. According to SciSparc, this trial advances its global development program with additional sites in the United States and Israel.

What is SCI-110 in the SciSparc (SPRC) Phase IIb Tourette Syndrome trial?

SCI-110 is a proprietary oral drug candidate combining dronabinol with palmitoylethanolamide for treating adult Tourette Syndrome. According to SciSparc, it is formulated to reduce tics and comorbid symptoms while aiming to minimize side effects, and is now in Phase IIb evaluation.

Where is the SciSparc (SPRC) Phase IIb SCI-110 trial for Tourette Syndrome being conducted?

The Phase IIb SCI-110 trial is being conducted at Hannover Medical School in Germany, Yale Child Study Center in Connecticut, and Tel Aviv Sourasky Medical Center in Israel. According to SciSparc, Hannover Medical School is one of the key clinical sites in this study.

What were the Phase IIa results supporting SciSparc’s (SPRC) Phase IIb SCI-110 trial?

The prior Phase IIa study showed an average 21% tic reduction across participants on the Yale Global Tic Severity Scale. According to SciSparc, these positive safety and efficacy findings provide the basis for the larger randomized, double-blind, placebo-controlled Phase IIb trial in adults.

What is the design of NeuroThera Labs’ Phase IIb SCI-110 trial for Tourette Syndrome?

The Phase IIb study is a randomized, double-blind, placebo-controlled, cross-over trial of daily oral SCI-110 in adults aged 18–65. According to SciSparc, primary efficacy is tic severity change at weeks 12 and 26, with safety monitored via adverse events.

What is the primary endpoint in the SciSparc (SPRC) Phase IIb SCI-110 Tourette Syndrome study?

The primary endpoint is change in tic severity measured by the Yale Global Tic Severity Scale at weeks 12 and 26 versus baseline. According to SciSparc, this endpoint will assess SCI-110’s efficacy in adults with Tourette Syndrome under controlled trial conditions.